Propel Bio Management, LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Propel Bio Management, LLC disclosed 20 US equity positions worth $117.1m in its Q4 2025 13F filing. The largest position was PAGPEUR at 20.8% of the reported book, followed by ACHV and PHAT. Against the Q3 2025 filing, it opened 8 new positions, added to 4 and reduced 3 among the top 20 holdings.
What did Propel Bio Management, LLC own in Q4 2025? Top 20 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | PAGPEUR PLAINS GP HLDGS L P | 20.8% | $24.4m | 1,272,360 | 0% | held | |
| 2 | ACHV ACHIEVE LIFE SCIENCES INC | 16.1% | $18.8m | 3,786,425 | 0% | held | |
| 3 | PHAT PHATHOM PHARMACEUTICALS INC | 10.5% | $12.3m | 740,918 | 34% | added | |
| 4 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 7.5% | $8.8m | 282,531 | 214% | added |
| 5 | MIST MILESTONE PHARMACEUTICALS | 7.1% | $8.3m | 4,118,321 | -20% | reduced | |
| 6 | KYTX KYVERNA THERAPEUTICS INC | 5.4% | $6.3m | 666,666 | – | new | |
| 7 | CMPS COMPASS PATHWAYS PLC | Healthcare | 5.1% | $5.9m | 861,778 | 69% | added |
| 8 | IVA INVENTIVA SA - ADR | 4.0% | $4.7m | 1,000,000 | – | new | |
| 9 | DCTH DELCATH SYSTEMS INC | 3.8% | $4.4m | 438,509 | 0% | held | |
| 10 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 3.7% | $4.4m | 830,780 | -15% | reduced |
| 11 | CLDX CELLDEX THERAPEUTICS INC | Healthcare | 3.6% | $4.2m | 154,300 | -0% | held |
| 12 | NKTR NEKTAR THERAPEUTICS | Healthcare | 3.0% | $3.5m | 82,822 | 69% | added |
| 13 | OCULIS HOLDING AG | 2.9% | $3.5m | 172,839 | – | new | |
| 14 | SABS SAB BIOTHERAPEUTICS INC | 2.1% | $2.4m | 652,881 | – | new | |
| 15 | RGNX REGENXBIO INC | Healthcare | 1.4% | $1.7m | 116,896 | – | new |
| 16 | LONA ATHIRA PHARMA INC | 1.0% | $1.1m | 149,279 | 0% | held | |
| 17 | LENZ LENZ THERAPEUTICS INC | Healthcare | 0.8% | $945.4k | 59,085 | – | new |
| 18 | AARD AARDVARK THERAPEUTICS INC | 0.5% | $609.1k | 46,408 | – | new | |
| 19 | ZVRA ZEVRA THERAPEUTICS INC | 0.5% | $570.6k | 63,683 | -73% | reduced | |
| 20 | KLRS KALARIS THERAPEUTICS INC | 0.3% | $354.9k | 42,053 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.